Weekly Highlights: Sylatron drug info, optical technology to treat cancer, and more
View web version
You are receiving this newsletter as a promotional effort on behalf of ChemotherapyAdvisor.com.
Click here to sign up to receive these newsletters on a regular basis.

Each week, Chemotherapy Advisor offers a briefing on the previous week's oncology articles.

Drug Showcase
SYLATRON® (peginterferon alfa-2b)

Review slide-by-slide drug information for SYLATRON® (peginterferon alfa-2b) for treatment of melanoma.

Feature Article
Attacking Cancer Cells Using Innovative Optical Technology
By
Latest News
Chronic Pancreatitis Ups Cancer Mortality Risk
Fewer Americans Overwhelmed by Medical Bills
Sebelius Resigns as HHS Secretary
Lipiodol Earns FDA Approval for Tumor Imaging in HCC
New Contest

It's time to go pro!

Now you can with our latest contest, Oncology Practice Pro.

Participate now for a chance to win a Nike Fuel Band!







Subscribe
If you were sent this by a colleague and wish to subscribe to Weekly highlights, please click here.

Unsubscribe
To unsubscribe from the Weekly Highlights click here.
To manage your entire Chemotherapy Advisor profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All Chemotherapy Advisor newsletters are sent from the domain "email.chemotherapyadvisor.com". When configuring e-mail or spam filter rules, please use this domain name.

Haymarket Media Inc
114 West 26th St 4th floor
New York, NY 10001